



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA

*Università degli Studi di Padova*

*Padua Research Archive - Institutional Repository*

Primary Coenzyme Q10 Deficiency

*Original Citation:*

*Availability:*

This version is available at: 11577/3223225 since: 2017-03-15T17:34:09Z

*Publisher:*

Roberta A Pagon, Editor-in-chief, Margaret P Adam, Holly H Ardinger, Stephanie E Wallace, Anne

*Published version:*

DOI:

*Terms of use:*

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.

## Primary Coenzyme Q<sub>10</sub> Deficiency

**Synonyms:** Coenzyme Q Deficiency, CoQ Deficiency, Primary CoQ<sub>10</sub> Deficiency, Ubiquinone Deficiency

Leonardo Salvati, MD, PhD, Eva **Trevisson**, MD, PhD, Mara Doimo, PhD, and Placido Navas, PhD.

Author Information

Initial Posting: January 26, 2017.

### Summary

---

**Clinical characteristics.** Primary coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) deficiency is usually associated with multisystem involvement, including neurologic manifestations such as fatal neonatal encephalopathy with hypotonia; a late-onset slowly progressive multiple-system atrophy-like phenotype (neurodegeneration with autonomic failure and various combinations of parkinsonism and cerebellar ataxia, and pyramidal dysfunction); and dystonia, spasticity, seizures, and intellectual disability. Steroid-resistant nephrotic syndrome (SRNS), the hallmark renal manifestation, is often the initial manifestation either as isolated renal involvement that progresses to end-stage renal disease (ESRD), or associated with encephalopathy (seizures, stroke-like episodes, severe neurologic impairment) resulting in early death. Hypertrophic cardiomyopathy (HCM), retinopathy or optic atrophy, and sensorineural hearing loss can also be seen.

**Diagnosis/testing.** The diagnosis of primary CoQ<sub>10</sub> deficiency in a proband is established by identification of biallelic pathogenic variants in one of the nine genes encoding proteins directly involved in the synthesis of coenzyme Q<sub>10</sub> or by detection of reduced levels of CoQ<sub>10</sub> (ubiquinone) in skeletal muscle or reduced activities of complex I+III and II+III of the mitochondrial respiratory chain on frozen muscle homogenates.

**Management.** *Treatment of manifestations:* In individuals with primary CoQ<sub>10</sub> deficiency early treatment with high-dose oral CoQ<sub>10</sub> supplementation (ranging from 5 to 50 mg/kg/day) can limit disease progression and reverse some manifestations; however, established severe neurologic and/or renal damage cannot be reversed. ACE inhibitors may be used in combination with CoQ<sub>10</sub> supplementation in persons with proteinuria; renal transplantation is an option for those with ESRD. Treatment of hypertrophic cardiomyopathy, retinopathy, and sensorineural hearing loss is per usual practice.

*Prevention of primary manifestations:* Supplementation with high-dose oral CoQ<sub>10</sub> can prevent progression of the renal disease and onset of neurologic manifestations.

*Surveillance:* Periodic neurologic evaluation, urine analysis (for proteinuria) and renal function tests, ophthalmologic evaluation, and audiometry.

*Evaluation of relatives at risk:* Presymptomatic diagnosis for the purpose of early treatment with CoQ<sub>10</sub> supplementation is warranted for relatives at risk.

**Genetic counseling.** Primary coenzyme Q<sub>10</sub> deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic diagnosis are possible if the pathogenic variants in a family are known.

### Diagnosis

---

Primary deficiency of coenzyme Q<sub>10</sub>, a lipid component of the mitochondrial respiratory chain, is

classified as a mitochondrial respiratory chain disorder [DiMauro et al 2013].

For this *GeneReview* the term ‘primary coenzyme Q<sub>10</sub> deficiency’ refers to the group of conditions characterized by a reduction of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) levels in tissues or cultured cells associated with mutation of the nine genes involved in the biosynthesis of coenzyme Q<sub>10</sub> (collectively called ‘*COQ* genes’).

There are no formal diagnostic criteria for primary coenzyme Q<sub>10</sub> deficiency.

### Suggestive Findings

Primary coenzyme Q<sub>10</sub> deficiency, which is associated with an extremely heterogeneous group of clinical manifestations, should be suspected in individuals with the following clinical findings (Table 1).

#### Clinical findings

- Steroid-resistant nephrotic syndrome (SRNS) without mutation of *NPHS1* (encoding nephrin) or *NPHS2* (encoding podocin), especially when accompanied by deafness, retinopathy, and/or other CNS manifestations [Emma et al 2012, Desbats et al 2015a]
- Clinical features of a mitochondrial encephalomyopathy, including neurologic findings (hypotonia, seizures, dystonia, nystagmus, cerebellar ataxia or pyramidal dysfunction, spasticity, peripheral neuropathy, and intellectual disability), myopathy, retinopathy, or optic atrophy, sensorineural hearing loss, and/or hypertrophic cardiomyopathy (Table 1).
- Unexplained ataxia (especially if family history suggests autosomal recessive inheritance) [Rahman et al 2012]
- Subacute exercise intolerance (with onset usually between ages 6 and 33 years) with proximal muscle weakness and elevated CK ( $\leq 20$  times upper limit of the control range) [Rahman et al 2012]

**Table 1.**

Clinical Manifestations Associated with Mutation of Genes Encoding Proteins Directly Involved in the Synthesis of Coenzyme Q<sub>10</sub>

Gene	Clinical Manifestations					
	Renal	Heart	Eye	Hearing	Neurologic	Muscle
<i>COQ2</i>	SRNS	HCM	Retinopathy	SNHL	Encephalopathy <sup>1</sup> Seizures Other <sup>2</sup>	Myopathy
<i>COQ4</i>		Heart failure HCM			Encephalopathy Seizures Other <sup>3</sup>	Myopathy
<i>COQ6</i>	SRNS <sup>4</sup>			SNHL	Encephalopathy Seizures	
<i>COQ7</i>					Encephalopathy ID Peripheral neuropathy	Muscle weakness
<i>COQ8A</i>					Encephalopathy Cerebellar ataxia Dystonia Spasticity	Exercise intolerance

Gene	Clinical Manifestations					
	Renal	Heart	Eye	Hearing	Neurologic	Muscle
					Seizures	
<i>COQ8B</i>	SRNS <sup>4</sup>				ID	
<i>COQ9</i>	Tubulopathy	HCM			Encephalopathy	Myopathy
<i>PDSS1</i>			Optic atrophy		Encephalopathy Peripheral neuropathy	
<i>PDSS2</i>	SRNS		Retinopathy	SNHL	Leigh syndrome Ataxia	

Table contents are ordered by gene.

HCM = hypertrophic cardiomyopathy

ID = intellectual disability

SNHL = sensorineural hearing loss

SRNS = steroid-resistant nephrotic syndrome

1. Encephalopathy comprises a wide spectrum of brain involvement with different clinical and neuroradiologic features, often not further explicated by the reporting authors.
2. Adult-onset multisystem atrophy-like phenotype [Desbats et al 2016]
3. Severe hypotonia, respiratory insufficiency, cerebellar hypoplasia, slowly progressive neurologic deterioration
4. Because individuals with *COQ6*- and *COQ8B*- related coenzyme Q<sub>10</sub> deficiency were ascertained by the presence of SRNS, the authors cannot exclude the possibility that biallelic pathogenic variants in these two genes could also cause a broader phenotype.

**Laboratory findings.** Serum or plasma lactate concentration may be high in those individuals with severe neonatal onset. Of note, normal lactate levels do not exclude the possibility of coenzyme Q<sub>10</sub> deficiency [Rahman et al 2012].

CSF lactate concentration may be more sensitive than serum/plasma levels, but can be normal.

### Establishing the Diagnosis

The diagnosis of primary coenzyme Q<sub>10</sub> deficiency in a proband **is established** by identification of biallelic pathogenic variants in one of the nine genes encoding proteins directly involved in the synthesis of coenzyme Q<sub>10</sub> (Table 2).

Note: If a diagnosis of primary coenzyme Q<sub>10</sub> deficiency cannot be established by molecular genetic testing, biochemical testing may be considered.

### Molecular Genetic Testing

Molecular testing approaches can include **single-gene testing**, use of a **multi-gene panel**, and **more comprehensive genomic testing**.

- **Serial single gene testing** based on clinical findings (see Table 1). Sequence analysis is performed first, followed by deletion/duplication analysis if only one or no pathogenic variant is identified.
- **Use of a multi-gene panel** that includes the nine genes in Table 2 and some or all of the other genes of interest; for example, genes:
  - Known (or suspected) to be required for CoQ<sub>10</sub> biosynthesis but not identified to

date as a cause of primary CoQ<sub>10</sub> deficiency (i.e., *ADCK1*, *ADCK2*, *ADCK5*, *COQ3*, *COQ10a*, *COQ10b*, *FDXR*, and *FDX2 (FDXIL)* [Desbats et al 2015a])

- Associated with secondary deficiencies of coenzyme Q<sub>10</sub> (*APTX*, *BRAF*, *ETFDH*) (see [Differential Diagnosis](#))
- Associated with a specific phenotype (e.g., steroid-resistant nephrotic syndrome, ataxia)

Note: (1) The choice of the specific panel depends on the phenotype observed in the patient. (2) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time.

- **More comprehensive genomic testing.** Because of the large (and still growing) number of genes involved, the rarity of primary coenzyme Q<sub>10</sub> deficiency, the incomplete knowledge of the coenzyme Q<sub>10</sub> biosynthetic pathway, and the continuous reduction in the cost of genomic testing, exome sequencing is an alternative to the use of single-gene testing and specific multi-gene panels [Desbats et al 2015a, Desbats et al 2015b]. In fact, exome sequencing may also be able to detect all possible genetic causes of both primary and secondary coenzyme Q<sub>10</sub> deficiency (see [Differential Diagnosis](#)). For more information on comprehensive genome sequencing click [here](#).

**Table 2.**

Summary of Molecular Genetic Testing Used in Primary Coenzyme Q<sub>10</sub> Deficiency

Gene <sup>1</sup>	Number of Families w/Coenzyme Q <sub>10</sub> Deficiency Attributed to Mutation of This Gene	Proportion of Pathogenic Variants <sup>2</sup> Detected by Test Method	
		Sequence analysis <sup>3</sup>	Gene-targeted deletion/duplication analysis <sup>4</sup>
<i>COQ2</i>	10 <sup>5</sup>	All pathogenic variants reported to date	Unknown
<i>COQ4</i>	9 <sup>6</sup>	All pathogenic variants reported to date	Unknown <sup>7</sup>
<i>COQ6</i>	5 <sup>8</sup>	All pathogenic variants reported to date	Unknown
<i>COQ7</i>	1 <sup>9</sup>	All pathogenic variants reported to date	Unknown
<i>COQ8A</i>	14 <sup>10</sup>	All pathogenic variants reported to date	Unknown <sup>11</sup>
<i>COQ8B</i>	34 <sup>12</sup>	Most pathogenic variants reported to date	Unknown
<i>COQ9</i>	2 <sup>13</sup>	All pathogenic variants reported to date	Unknown

Gene <sup>1</sup>	Number of Families w/Coenzyme Q <sub>10</sub> Deficiency Attributed to Mutation of This Gene	Proportion of Pathogenic Variants <sup>2</sup> Detected by Test Method	
		Sequence analysis <sup>3</sup>	Gene-targeted deletion/duplication analysis <sup>4</sup>
<i>PDSSI</i>	2 <sup>14</sup>	All pathogenic variants reported to date	Unknown
<i>PDSS2</i>	2 <sup>15</sup>	All pathogenic variants reported to date	Unknown
Unknown <sup>16</sup>	NA	NA	

1. See [Table A. Genes and Databases for chromosome locus and protein.](#)
2. See [Molecular Genetics](#) for information on allelic variants detected in this [gene](#).
3. Sequence analysis detects variants that are benign, likely benign, of [uncertain significance](#), likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and [splice site variants](#); typically, [exon](#) or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of [sequence analysis](#) results, click [here](#).
4. Gene-targeted [deletion/duplication analysis](#) detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a [gene-targeted microarray](#) designed to detect single-exon deletions or duplications.
5. [Quinzii et al \[2006\]](#), [Diomedi-Camassei et al \[2007\]](#), [Mollet et al \[2007\]](#), [Dinwiddie et al \[2013\]](#), [Jakobs et al \[2013\]](#), [McCarthy et al \[2013\]](#), [Mitsui et al \[2013\]](#), [Scalais et al \[2013\]](#), [Desbats et al \[2015b\]](#), [Desbats et al \[2016\]](#)
6. [Salviati et al \[2012\]](#), [Brea-Calvo et al \[2015\]](#), [Chung et al \[2015\]](#)
7. To date only one individual has had a heterozygous [deletion encompassing COQ4](#) [[Salviati et al 2012](#)].
8. [Heeringa et al \[2011\]](#), [Doimo et al \[2014\]](#)
9. [Freyer et al \[2015\]](#)
10. [Lagier-Tourenne et al \[2008\]](#), [Mollet et al \[2008\]](#), [Anheim et al \[2010\]](#), [Gerards et al \[2010\]](#), [Horvath et al \[2012\]](#), [Terracciano et al \[2012\]](#), [Mignot et al \[2013\]](#), [Blumkin et al \[2014\]](#), [Liu et al \[2014\]](#)
11. A [deletion from exon 3 to exon 15](#) has been described [[Lagier-Tourenne et al 2008](#)]
12. [Ashraf et al \[2013\]](#), [Korkmaz et al \[2016\]](#)
13. [Duncan et al \[2009\]](#), [Rahman et al \[2012\]](#), [Danhauser et al \[2016\]](#)
14. [Mollet et al \[2007\]](#), [Vasta et al \[2012\]](#)
15. [Rötig et al \[2000\]](#), [Rahman et al \[2012\]](#)
16. To date many individuals with reduced CoQ<sub>10</sub> in cells or tissues lack a clear genetic diagnosis, making it impossible to distinguish between primary and secondary CoQ<sub>10</sub> deficiency [[Trevisson et al 2011](#)].

### Biochemical Testing

The following findings on biochemical testing can differentiate coenzyme Q<sub>10</sub> deficiency from other mitochondrial disorders with similar clinical findings, but cannot differentiate primary from secondary coenzyme Q<sub>10</sub> deficiency (see [Differential Diagnosis](#)).

- Reduced levels of CoQ<sub>10</sub> in skeletal muscle [[Montero et al 2008](#)]. Note: While coenzyme Q<sub>10</sub> measurements may be performed on cultured skin fibroblasts or blood mononuclear

cells, these tissues may not be reliable in detecting secondary coenzyme Q<sub>10</sub> defects [Yubero et al 2015].

- Reduced activities of complex I+III and II+III of the mitochondrial respiratory chain on frozen muscle homogenates. These enzymatic activities, which depend on endogenous coenzyme Q<sub>10</sub>, are reduced in persons with a defect in CoQ<sub>10</sub> even when isolated complex II and III respiratory chain activities are normal [Rahman et al 2012].

## Clinical Characteristics

---

### Clinical Description

The manifestations of primary coenzyme Q<sub>10</sub> deficiency vary (Table 1). Traditionally, clinical presentations have been classified into five distinct phenotypes: encephalomyopathy, cerebellar ataxia, severe infantile multisystem disease, steroid-resistant nephrotic syndrome, and isolated myopathy [Emmanuele et al 2012]. This classification is probably now outdated because the range of clinical phenotypes is much wider, and different combinations of findings with significant overlap have been identified. Furthermore, no individuals with molecularly confirmed primary CoQ<sub>10</sub> deficiency with isolated myopathy have been reported [Authors, personal observation], since most individuals reported with predominantly muscle disease have secondary coenzyme Q<sub>10</sub> deficiency [Doimo et al 2014] (see Differential Diagnosis).

The broad age of onset of primary coenzyme Q<sub>10</sub> deficiency is exemplified by *COQ2*-related coenzyme Q<sub>10</sub> deficiency, in which onset ranges from birth to the seventh decade.

The principal clinical manifestations of primary CoQ<sub>10</sub> deficiency (regardless of genetic cause) are summarized below [Desbats et al 2015a], and followed by a summary of the phenotypes of *COQ2*-, *COQ8A*-, and *COQ8B*-related CoQ<sub>10</sub> deficiencies, the three most common causes of primary coenzyme Q<sub>10</sub> deficiency.

### Principal Clinical Manifestations

**Neurologic.** Central nervous system (CNS) manifestations include encephalopathy (a wide spectrum of brain involvement with different clinical and neuroradiologic features often not further specified). In some individuals encephalopathy is associated with findings on neuroimaging resembling Leigh syndrome [López et al 2006] or MELAS (with stroke-like episodes) [Salviati et al 2005]. CNS manifestations often include seizures, dystonia, spasticity, and/or intellectual disability [López et al 2006, Mollet et al 2007, Heeringa et al 2011].

The age of onset and clinical severity range from fatal neonatal encephalopathy with hypotonia [Mollet et al 2007, Jakobs et al 2013] to a late-onset slowly progressive multiple-system atrophy (MSA)-like phenotype, a neurodegenerative disorder characterized by autonomic failure associated with various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction. This clinical picture resembling MSA with onset in the seventh decade was reported in two multiplex families with *COQ2*-related coenzyme Q<sub>10</sub> deficiency [Mitsui et al 2013].

Individuals with *COQ8A*-related coenzyme Q<sub>10</sub> deficiency display progressive cerebellar atrophy and ataxia with intellectual disability and seizures [Lagier-Tourenne et al 2008, Mollet et al 2008].

Peripheral neuropathy with absent deep tendon reflexes has been reported in the two sibs with *PDSSI*-related coenzyme Q<sub>10</sub> deficiency; the age at onset and frequency of this manifestation are not known.

Given the small number of affected individuals described to date, clinical data are insufficient to make any generalizations about other neurologic manifestations (e.g., dystonia, spasticity, seizures, intellectual disability).

**Renal.** Steroid-resistant nephrotic syndrome (SRNS), an unusual feature of mitochondrial

disorders, is a hallmark of primary CoQ<sub>10</sub> deficiency. If not treated with coenzyme Q<sub>10</sub> (see [Management](#)), SRNS usually progresses to end-stage renal disease (ESRD).

Renal involvement usually manifests as proteinuria in infancy. Affected individuals often present initially with SRNS that leads to ESRD, followed by an encephalomyopathy with seizures and stroke-like episodes resulting in severe neurologic impairment and ultimately death [[Rötig et al 2000](#), [Salviati et al 2005](#), [Heeringa et al 2011](#)].

Some affected individuals manifest only SRNS with onset in the first or second decade of life and slow progression to ESRD without extrarenal manifestations.

One of the two individuals in a family with *COQ9*-related coenzyme Q<sub>10</sub> deficiency manifested tubulopathy within a few hours after birth.

**Cardiac.** Hypertrophic cardiomyopathy (HCM) has been reported in:

- Neonatal-onset *COQ2*-related coenzyme Q<sub>10</sub> deficiency [[Scalais et al 2013](#)];
- *COQ4*-related coenzyme Q<sub>10</sub> deficiency manifesting as prenatal-onset HCM [[Brea-Calvo et al 2015](#)];
- *COQ9*-related coenzyme Q<sub>10</sub> deficiency manifesting as neonatal-onset lactic acidosis followed by a multisystem disease that included HCM [[Duncan et al 2009](#)]. The cardiac disease worsened despite treatment with CoQ<sub>10</sub>.

**Ocular.** Retinopathy is observed in some persons with *COQ2*-related coenzyme Q<sub>10</sub> deficiency [[Desbats et al 2016](#)].

Optic atrophy is present in some individuals with *PDSS1*-related coenzyme Q<sub>10</sub> deficiency [[Mollet et al 2007](#)] and *PDSS2*-related coenzyme Q<sub>10</sub> deficiency [[Rötig et al 2000](#), [Rahman et al 2012](#)]. Data regarding age of onset and course of the eye manifestations are not available.

**Hearing.** Sensorineural hearing loss, which is common in individuals with *COQ6*-related coenzyme Q<sub>10</sub> deficiency, is also observed in some individuals with *COQ2*-related coenzyme Q<sub>10</sub> deficiency [[Author, personal observation](#)].

**Muscle** findings include weakness and exercise intolerance. Muscle biopsy may show nonspecific signs of lipid accumulation and mitochondrial proliferation [[Trevisson et al 2011](#), [Desbats et al 2015b](#)].

**Prognosis.** Data on the prognosis of primary CoQ<sub>10</sub> deficiency are limited due to the small number of affected individuals reported to date. It is a progressive disorder, with variable rates of progression and tissue involvement depending on the gene that is mutated and the severity of the CoQ<sub>10</sub> deficiency.

Children with severe multisystem CoQ<sub>10</sub> deficiency generally die within the neonatal period or in the first year of life.

The only child reported with *COQ9*-related coenzyme Q<sub>10</sub> deficiency died before age two years of a progressive multisystem disorder [[Duncan et al 2009](#)].

Of note, supplementation with high-dose oral CoQ<sub>10</sub> can change the natural history of the disease by blocking progression of the renal disease and preventing the onset of neurologic manifestations in persons with biallelic pathogenic variants in *COQ2*, *COQ6*, *COQ8B*, and *PDSS2* [[Montini et al 2008](#); [Author, personal communication](#)].

#### **Phenotypes of *COQ2*-, *COQ8A*-, and *COQ8B*-Related Coenzyme Q<sub>10</sub> Deficiency**

***COQ2*.** The findings in affected individuals from the ten families described to date differ in severity and age of onset [[Mollet et al 2007](#), [Diomedi-Camassei et al 2007](#), [Dinwiddie et al 2013](#), [Jakobs et al 2013](#), [McCarthy et al 2013](#), [Mitsui et al 2013](#), [Scalais et al 2013](#), [Desbats et al 2015b](#)].



[Desbats et al 2016](#)].

The main clinical features include SRNS, which can be:

- Isolated [[Salviati et al 2005](#), [Diomedi-Camassei et al 2007](#), [McCarthy et al 2013](#)];
- Associated with encephalomyopathy [[Salviati et al 2005](#)] or severe multiple-system disease [[Diomedi-Camassei et al 2007](#), [Mollet et al 2007](#), [Jakobs et al 2013](#)];
- Associated with late-onset multiple-system atrophy with retinitis pigmentosa [[Mitsui et al 2013](#), [Desbats et al 2016](#)].

**COQ8A.** Affected individuals experience onset of muscle weakness and reduced exercise tolerance between ages 18 months and three years, followed by cerebellar ataxia (the predominant clinical feature) with severe cerebellar atrophy on MRI. The disease course varies, including both progressive and apparently self-limited ataxia. The ataxia may be:

- Isolated [[Lagier-Tourenne et al 2008](#)];
- Progressive with cerebellar atrophy in addition to intellectual disability, epilepsy, stroke-like episodes, and/or exercise intolerance [[Auré et al 2004](#), [Lagier-Tourenne et al 2008](#), [Mollet et al 2008](#), [Terracciano et al 2012](#)].

**COQ8B.** Affected individuals generally manifest SRNS in the second decade, and frequently evolve to end-stage kidney disease [[Ashraf et al 2013](#), [Korkmaz et al 2016](#)]. In addition, four affected individuals were reported with mild intellectual disability, two with occasional seizures, and one with retinitis pigmentosa.

### Genotype-Phenotype Correlations

To date the limited number of affected individuals reported for each related gene complicates the delineation of genotype-phenotype correlations.

The factors that determine the clinical variability observed in primary CoQ<sub>10</sub> deficiency are unknown. One possibility is that the residual activity of the mutated protein modulates the phenotype; however, experimental data to evaluate this hypothesis are lacking.

### Prevalence

The estimated overall incidence of primary coenzyme Q<sub>10</sub> deficiency is less than 1:100,000; no precise epidemiologic data are available [[Desbats et al 2015a](#)].

### Genetically Related (Allelic) Disorders

No phenotypes other than those discussed in this *GeneReview* are known to be associated with mutation of *COQ2*, *COQ4*, *COQ7*, *COQ8A*, *COQ8B*, *COQ9*, *PDSS1*, or *PDSS2*.

**COQ6.** Heterozygous germline pathogenic variants in *COQ6* have been associated with susceptibility to schwannomatosis, a finding that has been disputed [[Trevisson et al 2015](#)].

### Differential Diagnosis

Note: It is important to consider primary CoQ<sub>10</sub> deficiency in individuals with the following diverse presentations because primary CoQ<sub>10</sub> deficiency is potentially treatable.

**Mitochondrial encephalomyopathies.** See [Mitochondrial Disorders Overview](#). The clinical manifestations of mitochondrial encephalomyopathies and primary coenzyme Q<sub>10</sub> deficiency can often be indistinguishable, especially in the severe phenotypes.

**Steroid-resistant nephrotic syndrome (SRNS)** that results from mutation of other genes important for podocyte function (including *DGKE*, *LAMB2*, *NPHS1*, *NPHS2*, *PLCE1*, *PTPRO*, and *WT1*) is clinically indistinguishable from the SRNS resulting from primary CoQ<sub>10</sub> deficiency.

**Early onset ataxia.** See [Hereditary Ataxia Overview](#).

**Muscle disease/myopathy.** See [Limb-Girdle Muscular Dystrophy Overview](#) and [Congenital Muscular Dystrophy Overview](#).

**Secondary coenzyme Q<sub>10</sub> deficiencies** are those disorders in which reduction in CoQ<sub>10</sub> levels is caused by mutation of genes not directly related to coenzyme Q<sub>10</sub> biosynthesis [[Trevisson et al 2011](#)]. Molecular genetic testing is the only way to distinguish primary coenzyme Q<sub>10</sub> deficiency from secondary coenzyme Q<sub>10</sub> deficiencies.

## Management

---

### Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with primary coenzyme Q<sub>10</sub> deficiency, the following evaluations are recommended:

- Neurologic evaluation including brain MRI
- Renal evaluation with particular attention to the presence of proteinuria
- Cardiac evaluation including echocardiography with particular attention to possible hypertrophic cardiomyopathy
- Ophthalmologic evaluation with particular attention to possible retinopathy and optic atrophy
- Audiometry with particular attention to possible sensorineural hearing loss
- Consultation with a clinical geneticist and/or genetic counselor

### Treatment of Manifestations

#### Pharmacologic Treatment

**Coenzyme Q<sub>10</sub> supplementation.** Individuals with primary CoQ<sub>10</sub> deficiency may respond well to high-dose oral CoQ<sub>10</sub> supplementation (ranging from 5 to 50 mg/kg/day). Soluble formulations are apparently more bioavailable [[Desbats et al 2015a](#)].

Treatment should be instituted as early as possible [[Montini et al 2008](#)] because it can limit disease progression and reverse some manifestations; however, established severe neurologic and/or renal damage cannot be reversed.

Individuals with the following genetic causes of primary CoQ<sub>10</sub> deficiency apparently respond well to CoQ<sub>10</sub> supplementation:

- *COQ4*-related coenzyme Q<sub>10</sub> deficiency. Neurologic signs responded to CoQ<sub>10</sub> supplementation in a single individual reported to date with a [heterozygous deletion](#) encompassing *COQ4* [[Salviati et al 2012](#)]; no response was observed in patients reported by [Chung et al \[2015\]](#).
- *COQ6*-related coenzyme Q<sub>10</sub> deficiency. Homozygotes for the pathogenic variants p.Gly255Arg or p.Ala353Asp responded [[Heeringa et al 2011](#)].
- *COQ8B*-related coenzyme Q<sub>10</sub> deficiency. In a patient [homozygous](#) for a truncating pathogenic variant, edema resolved and proteinuria was significantly improved.
- *PDSS2*-related coenzyme Q<sub>10</sub> deficiency. The only kindred reported responded [[Rötig et al 2000](#)].

Data for response to CoQ<sub>10</sub> supplementation in individuals with mutation of other genes causing primary coenzyme Q<sub>10</sub> deficiency are limited or lacking:

- *COQ8A*-related coenzyme Q<sub>10</sub> deficiency. While most affected individuals respond poorly to CoQ<sub>10</sub> supplementation, three individuals had a favorable response: one had objective stabilization of ataxia [Lagier-Tourenne et al 2008]; one had a dramatic and long-lasting improvement of dystonia and myoclonus after six months of treatment; and in one tremor and drawing ability improved [Mignot et al 2013].
- *COQ9*-related coenzyme Q<sub>10</sub> deficiency. One patient with multiple-system disease characterized by intractable seizures, global developmental delay, hypertrophic cardiomyopathy, and renal tubular dysfunction did not respond to CoQ<sub>10</sub> supplementation; however, this may be due to late diagnosis [Duncan et al 2009].

Ineffective treatments (or those without validated effects) for individuals with primary coenzyme Q<sub>10</sub> deficiency include the following CoQ<sub>10</sub> derivatives:

- Ubiquinol, the reduced form of CoQ<sub>10</sub>, has recently become commercially available; however, data on the therapeutic dosage and its efficacy are still lacking.
- Short chain quinone analogs such as idebenone [Rötig et al 2000, López et al 2010] have been reported to cause clinical deterioration in individuals with CoQ<sub>10</sub> deficiency [Hargreaves 2014].

### Renal Disease

ACE inhibitors may be used in combination with CoQ<sub>10</sub> supplementation in individuals with proteinuria [Heeringa et al 2011].

Renal transplantation is an option for those with end-stage renal disease [Salviati et al 2005].

### Other

Treatment of hypertrophic cardiomyopathy, retinopathy, and sensorineural hearing loss is routine (see [Hypertrophic Cardiomyopathy](#) and [Hereditary Hearing Loss and Deafness](#)).

### Prevention of Primary Manifestations

Early CoQ<sub>10</sub> supplementation may prevent the onset of manifestations of primary CoQ<sub>10</sub> deficiency (see [Treatment of Manifestations](#)).

### Surveillance

While surveillance depends on the specific genetic defect and on the clinical manifestations (see [Table 1](#)), it should always include periodic evaluations of the following: neurologic findings, urine analysis (for proteinuria) and renal function, ophthalmologic findings, and hearing.

Note: Because cardiomyopathy to date has been found only in the most severe phenotype (i.e., neonatal onset), cardiac evaluation should be performed at the time of diagnosis, but not periodically unless cardiac involvement has been documented.

### Evaluation of Relatives at Risk

Given the importance of early CoQ<sub>10</sub> supplementation, it is appropriate to evaluate the sibs of a proband who has primary coenzyme Q<sub>10</sub> deficiency in order to identify as early as possible those sibs who would benefit from early initiation of treatment.

- If the pathogenic variants in the family are known, [molecular genetic testing](#) can be used to clarify the genetic status of at-risk sibs.
- If the pathogenic variants in the family are not known and the diagnosis has been established by biochemical findings, one can consider measuring CoQ<sub>10</sub> levels in skin fibroblasts of at-risk sibs [Desbats et al 2015b].

See [Genetic Counseling](#) for issues related to testing of at-risk relatives for [genetic counseling](#) purposes.

### Therapies Under Investigation

Search [ClinicalTrials.gov](#) for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

### Genetic Counseling

---

*Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.*

### Mode of Inheritance

Primary coenzyme Q<sub>10</sub> deficiency is generally inherited in an [autosomal recessive](#) manner.

Primary coenzyme Q<sub>10</sub> deficiency associated with a [de novo contiguous gene deletion](#) encompassing *COQ4* was reported in one individual [[Salviati et al 2012](#)].

### Risk to Family Members – Autosomal Recessive Inheritance

#### Parents of a proband

- The parents of an individual with a confirmed molecular genetic diagnosis of primary coenzyme Q<sub>10</sub> deficiency are obligate heterozygotes (i.e., carriers of a [pathogenic variant](#) in *COQ2*, *COQ4*, *COQ6*, *COQ7*, *COQ8A*, *COQ8B*, *COQ9*, *PDSS1*, or *PDSS2*).
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

#### Sibs of a proband

- At conception, each sib of an [affected](#) individual has a 25% chance of being affected, a 50% chance of being an asymptomatic [carrier](#), and a 25% chance of being unaffected and not a carrier.
- Heterozygotes are asymptomatic and are not at risk of developing the disorder.

**Offspring of a proband.** The offspring of an individual with a confirmed molecular genetic diagnosis of primary coenzyme Q<sub>10</sub> deficiency are obligate heterozygotes (i.e., carriers of a [pathogenic variant](#) in *COQ2*, *COQ4*, *COQ6*, *COQ7*, *COQ8A*, *COQ8B*, *COQ9*, *PDSS1*, or *PDSS2*).

**Other family members.** Each sib of the parents of a proband with a confirmed molecular genetic diagnosis of primary coenzyme Q<sub>10</sub> deficiency is at a 50% risk of being a [carrier of a pathogenic variant](#).

### Heterozygote (Carrier) Detection

Carrier testing for at-risk relatives requires prior identification of the *COQ2*, *COQ4*, *COQ6*, *COQ7*, *COQ8A*, *COQ8B*, *COQ9*, *PDSS1*, or *PDSS2* pathogenic variants in the family.

### Related Genetic Counseling Issues

See [Management, Evaluation of Relatives at Risk](#) for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

## Family planning

- The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

**DNA banking** is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

## Prenatal Testing and Preimplantation Genetic Diagnosis

Once the *COQ2*, *COQ4*, *COQ6*, *COQ7*, *COQ8A*, *COQ8B*, *COQ9*, *PDSS1*, or *PDSS2* pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for primary coenzyme Q<sub>10</sub> deficiency are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

## Resources

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **Medline Plus**  
Coenzyme Q-10

## Molecular Genetics

*Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information.* —ED.

### Table A.

Primary Coenzyme Q10 Deficiency: Genes and Databases

Gene	Chromosome Locus	Protein	Locus Specific	HGMD
<a href="#">COQ2</a>	<a href="#">4q21.22-q21.23</a>	Para-hydroxybenzoate--polyprenyltransferase, mitochondrial	<a href="#">COQ2 database</a>	<a href="#">COQ2</a>
<a href="#">COQ4</a>	<a href="#">9q34.11</a>	Ubiquinone biosynthesis protein <a href="#">COQ4</a> homolog, mitochondrial		<a href="#">COQ4</a>
<a href="#">COQ6</a>	<a href="#">14q24.3</a>	Ubiquinone biosynthesis monooxygenase <a href="#">COQ6</a> , mitochondrial		<a href="#">COQ6</a>
<a href="#">COQ7</a>	<a href="#">16p12.3</a>	5-demethoxyubiquinone hydroxylase, mitochondrial		<a href="#">COQ7</a>

<a href="#">COQ8A</a>	<a href="#">1q42.13</a>	Atypical kinase ADCK3, mitochondrial	<a href="#">ADCK3 database</a>	<a href="#">COQ8A</a>
<a href="#">COQ8B</a>	<a href="#">19q13.2</a>	Atypical kinase COQ8B, mitochondrial		<a href="#">COQ8B</a>
<a href="#">COQ9</a>	<a href="#">16q21</a>	Ubiquinone biosynthesis protein COQ9, mitochondrial	<a href="#">COQ9 database</a>	<a href="#">COQ9</a>
<a href="#">PDSS1</a>	<a href="#">10p12.1</a>	Decaprenyl-diphosphate synthase subunit 1	<a href="#">PDSS1 database</a>	<a href="#">PDSS1</a>
<a href="#">PDSS2</a>	<a href="#">6q21</a>	Decaprenyl-diphosphate synthase subunit 2	<a href="#">PDSS2 database</a>	<a href="#">PDSS2</a>

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus, locus name, critical region, complementation group from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD) to which links are provided, [click here](#).

### Table B.

OMIM Entries for Primary Coenzyme Q10 Deficiency ([View All in OMIM](#))

<a href="#">601683</a>	COQ7, S. CEREVISIAE, HOMOLOG OF; COQ7
<a href="#">606980</a>	COENZYME Q8A; COQ8A
<a href="#">607426</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1
<a href="#">607429</a>	PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 1; PDSS1
<a href="#">609825</a>	COQ2, S. CEREVISIAE, HOMOLOG OF; COQ2
<a href="#">610564</a>	PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 2; PDSS2
<a href="#">612016</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4
<a href="#">612837</a>	COQ9, S. CEREVISIAE, HOMOLOG OF; COQ9
<a href="#">612898</a>	COENZYME Q4, S. CEREVISIAE, HOMOLOG OF; COQ4
<a href="#">614647</a>	COQ6, S. CEREVISIAE, HOMOLOG OF; COQ6
<a href="#">614650</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6
<a href="#">614651</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2
<a href="#">614652</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3
<a href="#">614654</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5
<a href="#">615567</a>	COENZYME Q8B; COQ8B
<a href="#">616276</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7
<a href="#">616733</a>	COENZYME Q10 DEFICIENCY, PRIMARY, 8; COQ10D8

### Molecular Genetic Pathogenesis

The pathogenesis of primary CoQ<sub>10</sub> deficiency is still not clear and the molecular basis of the locus heterogeneity of this group of disorders remains to be elucidated. Although the bioenergetic defect plays a crucial role in the pathophysiology of CoQ<sub>10</sub> deficiency, CoQ<sub>10</sub> carries out a number of fundamental functions in cells (it is a cofactor of other mitochondrial dehydrogenases, an essential antioxidant, and a modulator of apoptosis), suggesting that other mechanisms are involved.

In fact, it has been shown in cells that severe CoQ<sub>10</sub> deficiency causes a marked reduction in ATP production without increased production of reactive oxygen species (ROS), while mild CoQ<sub>10</sub> deficiency is associated with high ROS production without significant impairment of cellular

bioenergetics [Quinzii et al 2010].

In addition, CoQ<sub>10</sub> deficiency impairs *de novo* pyrimidine synthesis, further contributing to disease pathogenesis [López-Martín et al 2007].

Note: In this section the genes associated with primary CoQ<sub>10</sub> deficiency are ordered by gene.

### COQ2

**Gene structure.** *COQ2* consists of seven exons [Forsgren et al 2004]. The open reading frame contains four in-frame ATG initiation codons (termed ATG1-4 [López-Martín et al 2007]); the third one produces a transcript similar to yeast *COQ2*. Human *COQ2* cDNA originating from ATG1, ATG2, and ATG3 (but not from ATG4) can complement the defective respiratory phenotype of yeast *COQ2*-null strains [Forsgren et al 2004, López-Martín et al 2007, Mollet et al 2007].

Note: The presence of multiple possible initiation codons has generated confusion in naming *COQ2* pathogenic variants. The majority of reports consider the most 5' ATG (ATG1) as the initiation codon and the longer transcript NM\_015697.7 as reference. *GeneReviews* adheres to this nomenclature. However, changes to this convention are possible; it was recently proposed to transition from legacy nomenclature to nucleotide 1 corresponding to the A of ATG4 [Desbats et al 2016].

**Benign variants.** Multiple rare benign *COQ2* variants have recently been associated with sporadic multiple-system atrophy [Mitsui et al 2013]; however, this finding is still under debate and further confirmation is needed [Mitsui et al 2013, Jeon et al 2014, Schottlaender & Houlden 2014, Sharma et al 2014].

The p.Val393Ala *COQ2* variant, which is relatively common in the Japanese population, has not been found in European or North American populations.

**Pathogenic variants.** *COQ2* was the first gene found to be mutated in individuals with primary CoQ<sub>10</sub> deficiency [Quinzii et al 2006]. *COQ2* pathogenic variants include mainly missense alleles; truncating variants have also been reported (Table 3).

To date *COQ2* pathogenic variants have been reported in ten families with primary CoQ<sub>10</sub> deficiency [Quinzii et al 2006, Diomedi-Camassei et al 2007, Mollet et al 2007, Dinwiddie et al 2013, Jakobs et al 2013, McCarthy et al 2013, Mitsui et al 2013, Scalais et al 2013, Desbats et al 2015b, Desbats et al 2016].

### Table 3.

Selected Pathogenic *COQ2* Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change (Alias <sup>1</sup> )	Reference Sequences
c.382A>G (232A>G)	p.Met128Val (Met78Val)	NM_015697.7 NP_056512.5
c.437G>A	p.Ser146Asn	
c.545T>G	p.Met182Arg	
c.590G>A	p.Arg197His	
c.683A>G	p.Asn228Ser	
c.890A>G	p.Tyr297Cys	
c.905C>T	p.Ala302Val	
c.1159C>T	p.Arg387Ter	

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change (Alias <sup>1</sup> )	Reference Sequences
c.1197delT (1198delT)	p.Asn401IlefsTer15	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. Variant designation that does not conform to current naming conventions

**Normal gene product.** *COQ2* encodes a 421-amino acid para-hydroxybenzoate:polyprenyltransferase (NP\_056512.5) required for the second step of the final reaction sequence of CoQ biosynthesis. *COQ2* catalyzes the condensation of 4-hydroxybenzoate with polyprenyl-pyrophosphate, generating the first membrane-bound CoQ intermediate [Ashby et al 1992].

The *COQ2* enzyme is highly conserved throughout evolution. The human protein contains a N-terminal mitochondrial leader sequence, two conserved putative substrate-binding domains (which are rich in aspartic acid residues) and six predicted trans-membrane helices [Forsgren et al 2004].

For information on yeast studies, see [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms](#), *COQ2*.

**Abnormal gene product.** All coenzyme Q<sub>10</sub> deficiency-related *COQ2* pathogenic variants reported to date act through a [loss-of-function](#) mechanism, reducing the polyprenyl-transferase activity, as proved by the lack of complementation in yeast strains harboring deletion in the *COQ2* ortholog [Mollet et al 2007] or by a reduced incorporation of radiolabeled substrates into CoQ<sub>10</sub> [Quinzii et al 2006]. Although [genotype-phenotype](#) correlations are still unclear, most *COQ2* pathogenic variants behave as [hypomorphic](#) alleles, retaining residual activity that may contribute to the phenotype.

All known *COQ2* pathogenic variants affect highly conserved amino acid residues. The variant c.890A>G changes a highly conserved tyrosine to cysteine at amino acid 297 within the third predicted transmembrane domain. Variants p.Ser146Asn and p.Arg197His are located in the putative substrate-binding site (UbiA), whereas p.Asn228Ser is located in the first putative transmembrane domain.

### **COQ4**

**Gene structure.** *COQ4* spans a region of about 12 kb and has two transcript variants (details in [Table A, Gene, COQ4](#)). The longer transcript [NM\\_016035.4](#) has seven exons. An alternate transcript ([NM\\_001305942.1](#)) is shorter and has four exons.

*COQ4* is ubiquitously expressed, with higher levels in liver, lung, and pancreas [Casarin et al 2008].

**Pathogenic variants.** *COQ4* pathogenic variants have been reported in eleven affected individuals from eight unrelated families [Brea-Calvo et al 2015, Chung et al 2015].

A patient with [haploinsufficiency](#) of *COQ4* due to a *de novo* 3.9-Mb deletion of [chromosome 9q34](#) and documented CoQ<sub>10</sub> deficiency in fibroblasts had encephalomyopathic manifestations [Salviati et al 2012].

### **Table 4.**

Selected *COQ4* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency



DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.155T>C	p.Leu52Ser	
c.190C>T	p.Pro64Ser	
c.421C>T	p.Arg141Ter	NM_016035.4
c.433C>G	p.Arg145Gly	NP_057119.2
c.521_523delCCA	p.Thr174del	
c.718C>T	p.Arg240Cys	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *COQ4* transcript NM\_016035.4 encodes coq4 isoform 1, which consists of 265 amino acids, localizes to mitochondria, and is required for CoQ<sub>10</sub> biosynthesis since it efficiently restores both growth in glycerol and CoQ content when expressed in a *COQ4*-null yeast strain.

An alternate transcript (NM\_001305942.1) encodes coq4 isoform 2, which has 100 amino acids and unknown function; it lacks the first 24 amino acids that specify the predicted mitochondrial targeting sequence [Casarin et al 2008].

The precise function of ubiquinone biosynthesis protein COQ4 in CoQ<sub>10</sub> biosynthesis is still unknown: the protein lacks enzymatic activity but in yeast it is thought to organize proteins encoded by other genes involved in the synthesis of CoQ<sub>10</sub> into a multi-enzymatic complex [Marbois et al 2009].

**Abnormal gene product.** Missense *COQ4* pathogenic variants expressed in yeast failed to complement a *COQ4*<sup>null</sup> yeast strain [Brea-Calvo et al 2015].

## COQ6

**Gene structure.** *COQ6* transcript variant 1 has 12 exons.

Among the 18 putative isoforms resulting from alternative splicing, two full-length transcript variants NM\_182476.2 and NM\_182480.2 (designated transcript variants 1 and 2, respectively) were found to be expressed in several tissues including kidney; however, the longer transcript variant 1 is more abundant than variant 2. The two isoforms differ in the use of alternative exon 1a or 1b and the splicing of exon 3 (absent in isoform b) [Heeringa et al 2011, Doimo et al 2014] (see details in Table A, **Gene**, *COQ6*).

**Pathogenic variants.** Two homozygous missense pathogenic variants, c.763G>A and c.1058C>A, and two heterozygous nonsense pathogenic variants, c.1341G>A and c.1383delG, were found in four different families with steroid-resistant nephrotic syndrome (SRNS) [Heeringa et al 2011].

Variant c.763G>A was found in one family from northern Lebanon and one from southern Turkey, suggesting a possible founder effect [Heeringa et al 2011].

Two nonsense pathogenic variants, c.484C>T and c.564G>A, were found as single heterozygous pathogenic variants in two individuals with cyclosporine A-dependent nephrotic syndrome and diffuse mesangial sclerosis, respectively [Heeringa et al 2011].

The missense pathogenic variant, c.1235A>G, was found in the heterozygous state in another individual with SRNS [Doimo et al 2014].

### Table 5.

Selected *COQ6* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change	Predicted Protein Change (Alias <sup>1</sup> )	Reference Sequences
c.484C>T	p.Arg162Ter	NM_182476.2 NP_872282.1
c.564G>A	p.Trp188Ter	
c.763G>A	p.Gly255Arg	
c.1058C>A	p.Ala353Asp	
c.1235A>G	p.Tyr412Cys	
c.1341G>A	p.Trp447Ter	
c.1383delG	p.Ile462LeufsTer18 (Gln461fsTer478)	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. Variant designation that does not conform to current naming conventions

**Normal gene product.** COQ6 protein is a flavin-dependent monooxygenase involved in CoQ<sub>10</sub> synthesis [Ozeir et al 2011]. *COQ6* transcript variant 1 encodes isoform *a* (NP\_872282.1), a 468-amino acid protein (54 kd) containing a mitochondrial import sequence. Transcript variant 2 encodes isoform *b* (NP\_872286.2), a 443-amino acid protein (51 kd).

The human COQ6 isoform *a* localizes to mitochondria when overexpressed in several cell lines including podocytes. Under endogenous conditions it is expressed in glomeruli but not in tubules and localizes within cellular processes and Golgi apparatus [Heeringa et al 2011].

A pathogenic variant that reduced COQ6 expression (knockdown) in podocytes caused mitochondrial depolarization and increased the apoptotic rate through the intrinsic pathway, leading to growth defect. This phenotype was rescued by treating cells with CoQ<sub>10</sub> [Heeringa et al 2011].

For information on yeast studies, see [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms](#), **COQ6**.

**Abnormal gene product.** Alleles p.Trp447Ter, p.Gly255Arg, and p.Tyr412Cys did not rescue the respiratory deficiency of the *COQ6*-null yeast strain as did the wild-type, and p.Ala353Asp, and p.Ile462LeufsTer18 [Doimo et al 2014]. However, in vitro experiments suggest that all the alleles, with the exception of the nonsense allele p.Trp447Ter, are thought to be hypomorphic, because modeling of the human pathogenic variant on the correspondent yeast amino acid residue did not completely abolish the respiratory growth of the yeast strain. Finally, the phenotype of yeast expressing the human pathogenic alleles recovers after addition of vanillic acid or 3,4 dihydroxybenzoic acid [Doimo et al 2014].

The pathogenic variants p.Tyr412Cys and p.Ala353Asp affect an amino acid located at the flavin adenine dinucleotide (FAD) binding domain and may negatively interfere with COQ6 binding to FAD. The p.Gly255Arg variant, which affects a residue located in the active site pocket, and the p.Trp447Ter and p.Ile462LeufsTer18 variants, affecting residues located at the C-terminal tail, may cause perturbation of the active site [Doimo et al 2014].

**COQ7**

**Gene structure.** *COQ7* has two transcript variants each comprising six exons. They differ in the first exon; the longer transcript (NM\_016138.4) encodes a 217-amino acid long protein

(NP\_057222.2), whereas the shorter transcript (NM\_001190983.1) uses an alternate 5' exon, resulting in a downstream AUG start codon with a shorter N-terminus resulting in a 170-amino acid protein (NP\_001177912.1). See [Table A](#), **Gene**, *COQ7* for a detailed summary of gene and protein information.

**Pathogenic variants.** A single affected individual born to consanguineous parents has been reported to date [Freyer et al 2015] harboring a homozygous c.422T>A missense variant. The patient manifested mild learning disabilities, muscular hypotonia, and hearing and visual impairment.

#### Table 6.

Selected *COQ7* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.422T>A	p.Val141Glu	NM_016138.4 NP_057222.2

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *COQ7* is a mitochondrial di-iron oxidase responsible for the penultimate step of CoQ synthesis, hydroxylating 5-demethoxyubiquinol (DMQH<sub>2</sub>) in the presence of NADH.

**Abnormal gene product.** The variant p.Val141Glu likely affects enzymatic function by impairing iron binding. Of note, supplementation of fibroblasts from the affected individual with 2,4-dihydroxybenzoic acid resulted in increased CoQ<sub>10</sub> content and restored the combined activities of Complex I+III and II+III [Freyer et al 2015].

#### *COQ8A*

**Gene structure.** *COQ8A* (previous symbols: *ADCK3*, *COQ8*, *CABC1*) comprises 15 exons. Alternatively spliced transcript variants have been found; however, their full-length nature has not been determined. The gene is ubiquitously expressed, with greater abundance in heart and skeletal muscle [Iizumi et al 2002].

**Pathogenic variants.** *COQ8A* pathogenic variants causing autosomal recessive ataxia associated with CoQ deficiency have been described extensively [Lagier-Tourenne et al 2008, Mollet et al 2008, Anheim et al 2010, Gerards et al 2010, Horvath et al 2012, Terracciano et al 2012, Mignot et al 2013, Blumkin et al 2014, Liu et al 2014, Barca et al 2016, Hikmat et al 2016].

More than 20 pathogenic variants have been reported, including missense, nonsense, and frameshift variants and a multiexon deletion (from exon 3 to exon 15).

To date all pathogenic variants reported are private and no founder effect has been identified.

#### Table 7.

Selected *COQ8A* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change	Reference Sequences
c.637C>T (636C>T)	p.Arg213Trp	NM_020247.4 NP_064632.2

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change	Reference Sequences
c.811C>T	p.Arg271Cys	
c.815G>A	p.Gly272Asp	
c.815G>T	p.Gly272Val	
c.895C>T	p.Arg299Trp	
c.993C>T <sup>2</sup>	p.Leu314_Gln360del	
c.1042C>T	p.Arg348Ter	
c.1081-1_1082dupGTA	--	
c.1136T>A	p.Leu379Ter	
c.1398+2T>C <sup>3</sup>		
c.1523T>C	p.Phe508Ser	
c.1541A>G	p.Tyr514Cys	
c.1645G>A	p.Gly549Ser	
c.1651G>A (1655G>A)	p.Glu551Lys	
c.1750_1752delACC	p.Thr584del	
c.1813dupG (1812_1813insG)	p.Glu605GlyfsTer125	
c.1844dupG (1844_1845insG)	p.Ser616LeufsTer114	
c.1844G>A	p.Gly615Asp	
g.227150977_227195656del44680 See footnote 4		<u>NC_000001.10</u> <sup>5</sup>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. Variant designation that does not conform to current naming conventions
2. Causes the skipping of exon 8 leading to an in-frame deletion of 47 amino acids (p.Lys314\_Gln360del) [[Lagier-Tourenne et al 2008](#)]
3. Results in the formation of at least two different abnormal splicing variants [[Lagier-Tourenne et al 2008](#)]
4. [Mignot et al \[2013\]](#); 29-kb deletion of exons 3 to 15 (hg19)
5. Genome assembly hg19

**Normal gene product.** *COQ8A* encodes a 647-amino acid protein that belongs to the UbiB protein kinase-like family and contains the conserved kinase motif in the region responsible for ATP binding and phosphotransfer reaction, but lacks the conserved kinase C-term motif. Moreover, it presents an N-terminal domain that is absent in the other proteins of the kinase family and it appears to be specifically related to ubiquinone metabolism [[Stefely et al 2015](#)].

In humans there are five paralogs belonging to the aarF domain-containing protein kinase (ADCK1-5); among them, *COQ8A* and *COQ8B* are highly similar and both are involved in CoQ<sub>10</sub> biosynthesis [[Lagier-Tourenne et al 2008](#), [Ashraf et al 2013](#)]. *COQ8A* localizes in mitochondria.

Computational and in vitro analyses prove that COQ8A forms homodimers after dimerization at the level of the transmembrane alpha-helices [Khadria et al 2014] and that the kinase motif displays magnesium (Mg<sup>2+</sup>)-dependent ATPase activity [Wheeler & Jia 2015].

For information on yeast studies, see [Coenzyme Q10 Deficiency – Model Organisms](#), **COQ8A**.

**Abnormal gene product.** The variants p.Arg213Trp, p.Gly272Val, p.Gly272Asp, and p.Glu551Lys predict changes in highly conserved amino acids of the protein, although none are in the kinase motifs [Mollet et al 2008].

The p.Tyr514Cys allele affects a residue proximal to the aspartates that bind the magnesium ions chelated by ATP [Lagier-Tourenne et al 2008].

The 1-bp frameshift insertion c.1813dupG results in the formation of a longer abnormal product (728 amino acids) and it is thought to modify an important domain of the protein altering the putative interaction or regulation between COQ8A and COQ9 [Mollet et al 2008].

The homozygous frameshift pathogenic variant p.Ser616LeufsTer114 causes the loss of the stop codon, leading to a 81-amino acid longer protein. The patient had significant CoQ<sub>10</sub> deficiency and reduced mitochondrial respiratory chain enzyme activity.

The two nonsense pathogenic variants p.Arg348Ter and p.Leu379Ter cause a premature stop codon that triggers nonsense-mediated mRNA decay, leading to complete absence of functional COQ8A protein. Due to its regulatory role and to the presence of at least another ADCK protein with similar function (although patients with mutation of *COQ8A* do not have COQ8B up-regulation), the complete lack of residual functional protein is compatible with life [Gerards et al 2010].

The c.1081-1\_1082dupGTA pathogenic variant does not alter the splicing of the transcript but causes insertion of three nucleotides, resulting in a stop codon [Mignot et al 2013].

The p.Phe508Ser variant is localized in one motif of the kinase domain [Mignot et al 2013].

The p.Gly549Ser and p.Gly615Asp pathogenic variants are in the C-terminal domain common to *COQ8A* and *COQ8B* [Lagier-Tourenne et al 2008, Mignot et al 2013].

### COQ8B

**Gene structure.** *COQ8B* spans 12 kb. Among the hypothetical 17 putative alternative splicing variants, the longest transcript [NM\\_024876.3](#) contains 15 exons; exon 1 is non-coding [Ashraf et al 2013].

**Pathogenic variants.** Recessive loss-of-function pathogenic variants in *COQ8B* have been described in patients with steroid-responsive nephrotic syndrome (SRNS) associated with primary CoQ<sub>10</sub> deficiency [Ashraf et al 2013].

### Table 8.

Selected *COQ8B* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.101G>A	p.Trp34Ter	<a href="#">NM_024876.3</a> <a href="#">NP_079152.3</a>
c.532C>T	p.Arg178Trp	
c.645delT	p.Phe214LeufsTer14	
c.857A>G	p.Asp286Gly	
c.954_956dup	p.Thr319dup	
c.958C>T	p.Arg320Trp	
c.1027C>T	p.Arg343Trp	

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.1199dupA	p.His400AsnfsTer11	
c.1356_1362delGGGCCCT	p.Gln452HisfsTer261	
c.1430G>A	p.Arg477Gln	
c.1447G>T	p.Glu483Ter	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** Transcript variant [NM\\_024876.3](#) encodes isoform *a*, which is a 60.1-kD protein that contains a helical domain, an ABC1 domain, and a kinase domain [Ashraf et al 2013]. COQ8B is one of the five ADCK paralogs and is highly similar to COQ8A, a putative kinase involved in CoQ<sub>10</sub> biosynthesis [Lagier-Tourenne et al 2008]. It is conserved in several species and displays high sequence similarity with *S. cerevisiae* Coq8/Abc1 protein [Ashraf et al 2013].

In humans, COQ8A expression exceeds COQ8B in several tissues with the exception of kidney. COQ8B is highly expressed in podocyte cell bodies and primary processes and, to a lesser extent, in renal glomeruli and in proximal tubules and collecting ducts. Analysis of subcellular fractions from cultured podocytes reveals that COQ8B resides both in mitochondria and cytosol, suggesting a localized function at ruffles and foot processes of podocytes besides its role in CoQ biosynthesis [Ashraf et al 2013].

See also [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms](#), **COQ8B**.

**Abnormal gene product.** All the reported missense pathogenic variants affect conserved residues. Patients have reduced levels of CoQ<sub>10</sub> in both primary skin fibroblasts and lymphoblastoid-derived cells.

All individuals with biallelic pathogenic variants in *COQ8B* have SRNS; however, the phenotype depends on the genotype [Ashraf et al 2013]:

- The patient homozygous for the p.His400AsnfsTer11 truncating variant had the earliest onset and developmental delay.
- The patient homozygous for the p.Arg178Trp amino acid change had diffuse glomerulosclerosis.
- Homozygosity for the p.Gln452HisfsTer261 pathogenic variant was found in two sibs of Indian ancestry with renal histology and collapsing focal segmental glomerulosclerosis (cFSGS). Notably, cFSGS is common in individuals with mutation of *COQ8B* as well as in the pdss2 kd/kd mouse model [Saiki et al 2008, Ashraf et al 2013].

## COQ9

**Gene structure.** *COQ9* has nine exons. No alternative splicing variants are known.

**Pathogenic variants.** One patient of Pakistani origin with multiple-system disease characterized by intractable seizures, global developmental delay, hypertrophic cardiomyopathy, and renal tubular dysfunction was homozygous for the c.730C>T pathogenic variant in exon 7 resulting in a premature stop codon (p.Arg244Ter) [Duncan et al 2009].

The homozygous loss-of-function variant c.521+1del was reported in a child of Turkish origin with fatal neonatal lactic acidosis and encephalopathy [Danhauser et al 2016].

### Table 9.

Selected *COQ9* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.521+1delG		NM_020312.3
c.730C>T	p.Arg244Ter	NP_064708.1

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *COQ9* encodes a 318-amino acid protein that is involved in the synthesis of CoQ<sub>10</sub> [Duncan et al 2009].

The crystal structure of the human protein reveals that COQ9 is homologous to the TetR family of transcriptional regulators but does not retain any DNA binding ability. It is organized as a homodimer and contains a hydrophobic pocket, responsible for binding of lipid molecules (likely CoQ<sub>10</sub> or CoQ<sub>10</sub> precursor) and a binding surface crucial for protein-protein interaction with Coq7 [Lohman et al 2014].

See also [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms, \*COQ9\*](#).

**Abnormal gene product.** The c.730C>T pathogenic variant is presumed to cause nonsense-mediated mRNA decay, as no transcript was detected in patient fibroblasts.

The c.521+1del pathogenic variant affects splicing with the skipping of exons 4 and 5 (p.Ser127\_Arg202del), as shown by sequencing of the *COQ9* transcript in the patient's fibroblasts, with consequent degradation of the truncated protein [Danhauser et al 2016].

See also [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms, \*COQ9\*](#).

***PDSS1***

**Gene structure.** *PDSS1* spans more than 49.14 kb and comprises 12 exons. There is only one coding transcript, which is 1,679 bp long.

**Pathogenic variants.** *PDSS1* pathogenic variants have been identified in only two families with primary CoQ<sub>10</sub> deficiency to date:

- Two sibs with encephalopathy, peripheral neuropathy, optic atrophy, cardiac valvulopathy, and mild lactic acidosis were homozygous for the c.924T>G missense variant in exon 10 [Mollet et al 2007].
- An individual with developmental delay, nephrotic syndrome, and failure to thrive was compound heterozygous for two novel variants: c.661\_662insT and c.1108A>C [Vasta et al 2012].

**Table 10.**Selected *PDSS1* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change	Reference Sequences
c.661_662insT (661C>CT)	p.Arg221LeufsTer16	NM_014317.3
c.924T>G (977T>G)	p.Asp308Glu	NP_055132.2

DNA Nucleotide Change (Alias <sup>1</sup> )	Predicted Protein Change	Reference Sequences
c.1108A>C (1108A>AC)	p.Ser370Arg	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. Variant designation that does not conform to current naming conventions

**Normal gene product.** *PDSS1* encodes decaprenyl-diphosphate synthase subunit 1 (previously reported as DPS1) which is required for the synthesis of the polyisoprenoid chain of the appropriate length, the first step in CoQ<sub>10</sub> biosynthesis. The protein is composed of 415 amino acids.

It is an ortholog of *Schizosaccharomyces pombe* Dps1. Unlike in *S. cerevisiae* where the ubiquinone side chain is synthesized by the monomeric enzyme COQ1, in *S. pombe* and in mammals the PDSS1 polypeptide interacts with the product of *PDSS2* forming a heterotetramer that is responsible for the elongation of the prenyl side chain of CoQ<sub>10</sub> and determines the isoprenoid chain length of ubiquinone [Saiki et al 2005].

**Abnormal gene product.** In the absence of *PDSS1*, decaprenyl-diphosphate synthase is not functional and does not produce CoQ<sub>10</sub>.

For information on yeast studies, see [Coenzyme Q<sub>10</sub> Deficiency – Model Organisms](#), *PDSS1*.

### **PDSS2**

**Gene structure.** The gene has at least two different transcript variants that share the first three exons; only the longest (NM\_020381.3), which has eight exons, is believed to encode a functional subunit of the decaprenyl diphosphate synthase [Saiki et al 2005].

**Pathogenic variants.** To date *PDSS2* pathogenic variants have been reported in two families; the phenotypes ranged from fatal Leigh syndrome and nephrotic syndrome to infantile-onset encephalomyopathy with ataxia, deafness, retinitis pigmentosa, and kidney disease [Rötig et al 2000, López-Martín et al 2007, Rahman et al 2012]. The patient reported by López-Martín et al [2007] was compound heterozygous for two novel variants, c.964C>T and c.1145C>T.

#### **Table 11.**

Selected *PDSS2* Pathogenic Variants that Cause Primary CoQ<sub>10</sub> Deficiency

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.964C>T	p.Gln322Ter	NM_020381.3
c.1145C>T	p.Ser382Leu	NP_065114.3

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** The protein product of *PDSS2* (previously reported as DLP1) is the second subunit of decaprenyl diphosphate synthase, which is required for the elongation of the prenyl side chain of CoQ<sub>10</sub>. The PDSS2 protein consists of 399 amino acids.



Unlike *S. cerevisiae*, the prenyl diphosphate synthase in humans acts as a heterotetrameric complex, formed by two protein subunits encoded by *PDSSI* and two protein subunits encoded by *PDSS2* [Saiki et al 2005]. The same heterotetrameric complex is also found in mice and *S. pombe*.

**Abnormal gene product.** In the absence of *PDSS2*, decaprenyl-diphosphate synthase is not functional and does not produce CoQ<sub>10</sub>. The *PDSS2* pathogenic variants reported by López-Martín et al [2007] act through a loss-of-function mechanism, as suggested by substrate incorporation experiments showing a CoQ<sub>10</sub> biosynthetic defect in fibroblasts from an affected individual when incubated with radioactive *para*-hydroxybenzoate (PHB), compared with normal synthesis in cells incubated with radiolabeled PHB and decaprenyl-PP.

For information on mouse studies, see [Coenzyme Q10 Deficiency – Model Organisms](#), *PDSS2*.

## References

---

### Literature Cited

1. Anheim M, Fleury M, Monga B, Laugel V, Chaigne D, Rodier G, Ginglinger E, Boulay C, Courtois S, Drouot N, Fritsch M, Delaunoy JP, Stoppa-Lyonnet D, Tranchant C, Koenig M. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, eastern France: implications for clinical management. *Neurogenetics*. 2010;11:1–12. [PubMed: 19440741]
2. Ashby MN, Kutsunai SY, Ackerman S, Tzagoloff A, Edwards PA. COQ2 is a candidate for the structural gene encoding para-hydroxybenzoate:polyprenyltransferase. *J Biol Chem*. 1992;267:4128–36. [PubMed: 1740455]
3. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, Fang H, Song X, Cattran DC, Avila-Casado C, Paterson AD, Nitschké P, Bole-Feysot C, Cochat P, Esteve-Rudd J, Haberberger B, Allen SJ, Zhou W, Airik R, Otto EA, Barua M, Al-Hamed MH, Kari JA, Evans J, Bierzynska A, Saleem MA, Böckenhauer D, Kleta R, El Desoky S, Hacıhamdioglu DO, Gok F, Washburn J, Wiggins RC, Choi M, Lifton RP, Levy S, Han Z, Salviati L, Prokisch H, Williams DS, Pollak M, Clarke CF, Pei Y, Antignac C, Hildebrandt F. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. *J Clin Invest*. 2013;123:5179–89. [PMC free article: PMC3859425] [PubMed: 24270420]
4. Auré K, Benoist JF, Ogier de Baulny H, Romero NB, Rigal O, Lombes A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. *Neurology*. 2004;63:727–9. [PubMed: 15326254]
5. Barca E, Musumeci O, Montagnese F, Marino S, Granata F, Nunnari D, Peverelli L, DiMauro S, Quinzii CM, Toscano A. Cerebellar ataxia and severe muscle CoQ10 deficiency in a patient with a novel mutation in ADCK3. *Clin Genet*. 2016;90:156–60. [PMC free article: PMC4950673] [PubMed: 26818466]
6. Blumkin L, Leshinsky-Silver E, Zerem A, Yosovich K, Lerman-Sagie T, Lev D. Heterozygous mutations in the ADCK3 gene in siblings with cerebellar atrophy and extreme phenotypic variability. *JIMD Rep*. 2014;12:103–7. [PMC free article: PMC3897800] [PubMed: 24048965]
7. Brea-Calvo G, Haack TB, Karall D, Ohtake A, Invernizzi F, Carrozzo R, Kremer L, Dusi S, Fauth C, Scholl-Bürgi S, Graf E, Ahting U, Resta N, Laforgia N, Verrigni D, Okazaki Y, Kohda M, Martinelli D, Freisinger P, Strom TM, Meitinger T, Lamperti C, Lacson A, Navas P, Mayr JA, Bertini E, Murayama K, Zeviani M, Prokisch H, Ghezzi D. COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency. *Am J Hum Genet*. 2015;96:309–17. [PMC free article: PMC4320255] [PubMed: 25658047]
8. Casarin A, Jimenez-Ortega JC, Trevisson E, Pertegato V, Doimo M, Ferrero-Gomez ML, Abbadì S, Artuch R, Quinzii C, Hirano M, Basso G, Ocaña CS, Navas P, Salviati L.

- Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. *Biochem Biophys Res Commun.* 2008;372:35–9. [PMC free article: [PMC4345104](#)] [PubMed: 18474229]
9. Chung WK, Martin K, J alas C, Braddock SR, Juusola J, Monaghan KG, Warner B, Franks S, Yudkoff M, Lulis L, Rhodes RH, Prasad V, Torti E, Cho MT, Shinawi M. Mutations in *COQ4*, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy. *J Med Genet.* 2015;52:627–35. [PubMed: 26185144]
  10. Danhauser K, Herebian D, Haack TB, Rodenburg RJ, Strom TM, Meitinger T, Klee D, Mayatepek E, Prokisch H, Distelmaier F. Fatal neonatal encephalopathy and lactic acidosis caused by a homozygous loss-of-function variant in *COQ9*. *Eur J Hum Genet.* 2016;24:450–4. [PMC free article: [PMC4755375](#)] [PubMed: 26081641]
  11. Desbats MA, Lunardi G, Doimo M, **Trevisson** E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. *J Inherit Metab Dis.* 2015a;38:145–56. [PubMed: 25091424]
  12. Desbats MA, Morbidoni V, Silic-Benussi M, Doimo M, Ciminale V, Cassina M, Sacconi S, Hirano M, Basso G, Pierrel F, Navas P, Salviati L, **Trevisson** E. The *COQ2* genotype predicts the severity of coenzyme Q10 deficiency. *Hum Mol Genet.* 2016. Epub ahead of print. [PubMed: 27493029]
  13. Desbats MA, Vetro A, Limongelli I, Lunardi G, Casarin A, Doimo M, Spinazzi M, Angelini C, Cenacchi G, Burlina A, Rodriguez Hernandez MA, Chiandetti L, Clementi M, **Trevisson** E, Navas P, Zuffardi O, Salviati L. Primary coenzyme Q(10) deficiency presenting as fatal neonatal multiorgan failure. *Eur J Hum Genet.* 2015b;23:1254–8. [PMC free article: [PMC4430297](#)] [PubMed: 25564041]
  14. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. *Nat Rev Neurol.* 2013;9:429–44. [PMC free article: [PMC3959773](#)] [PubMed: 23835535]
  15. Dinwiddie DL, Smith LD, Miller NA, Atherton AM, Farrow EG, Strenk ME, Soden SE, Saunders CJ, Kingsmore SF. Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome. *Genomics.* 2013;102:148–56. [PMC free article: [PMC4557607](#)] [PubMed: 23631824]
  16. Diomedì-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F. *COQ2* nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. *J Am Soc Nephrol.* 2007;18:2773–80. [PubMed: 17855635]
  17. Doimo M, **Trevisson** E, Airik R, Bergdoll M, Santos-Ocaña C, Hildebrandt F, Navas P, Pierrel F, Salviati L. Effect of vanillic acid on *COQ6* mutants identified in patients with coenzyme Q10 deficiency. *Biochim Biophys Acta.* 2014 Jan;1842(1):1–6. [PMC free article: [PMC3898990](#)] [PubMed: 24140869]
  18. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, López LC, Hirano M, Quinzii CM, Sadowski MI, Hardy J, Singleton A, Clayton PT, Rahman S. A nonsense mutation in *COQ9* causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. *Am J Hum Genet.* 2009;84:558–66. [PMC free article: [PMC2681001](#)] [PubMed: 19375058]
  19. Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. *Pediatr Nephrol.* 2012;27:539–50. [PMC free article: [PMC3288375](#)] [PubMed: 21656172]
  20. Emmanuele V, López LC, Berardo A, Naini A, Tadesse S, Wen B, D'Agostino E, Solomon M, DiMauro S, Quinzii C, Hirano M. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. *Arch Neurol.* 2012;69:978–83. [PMC free article: [PMC3639472](#)] [PubMed: 22490322]
  21. Forsgren M, Attersand A, Lake S, Grünler J, Swiezewska E, Dallner G, Climent I. Isolation and functional expression of human *COQ2*, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ. *Biochem J.* 2004;382:519–26. [PMC free article: [PMC1133808](#)] [PubMed: 15153069]
  22. Freyer C, Stranneheim H, Naess K, Mourier A, Felser A, Maffezzini C, Lesko N, Bruhn H, Engvall M, Wibom R, Barbaro M, Hinze Y, Magnusson M, Andeer R, Zetterström RH, von

- Döbeln U, Wredenberg A, Wedell A. Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybenzoic acid. *J Med Genet*. 2015;52:779–83. [PMC free article: PMC4680133] [PubMed: 26084283]
23. Gerards M, van den Bosch B, Calis C, Schoonderwoerd K, van Engelen K, Tijssen M, de Coo R, van der Kooi A, Smeets H. Nonsense mutations in *CABC1/ADCK3* cause progressive cerebellar ataxia and atrophy. *Mitochondrion*. 2010;10:510–5. [PubMed: 20580948]
24. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. *Int J Biochem Cell Biol*. 2014;49:105–11. [PubMed: 24495877]
25. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, **Trevisson E**, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, Rötig A, Nürnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakaloglu A, Bakaloglu SA, Müller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Ocaña C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, Nürnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest*. 2011;121:2013–24. [PMC free article: PMC3083770] [PubMed: 21540551]
26. Hikmat O, Tzoulis C, Knappskog PM, Johansson S, Boman H, Sztromwasser P, Lien E, Brodtkorb E, Ghezzi D, Bindoff LA. ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic? *Eur J Neurol*. 2016;23:1188–94. [PubMed: 27106809]
27. Horvath R, Czermin B, Gulati S, Demuth S, Houge G, Pyle A, Dineiger C, Blakely EL, Hassani A, Foley C, Brodhun M, Storm K, Kirschner J, Gorman GS, Lochmüller H, Holinski-Feder E, Taylor RW, Chinnery PF. Adult-onset cerebellar ataxia due to mutations in *CABC1/ADCK3*. *J Neurol Neurosurg Psychiatry*. 2012;83:174–8. [PubMed: 22036850]
28. Iizumi M, Arakawa H, Mori T, Ando A, Nakamura Y. Isolation of a novel gene, *CABC1*, encoding a mitochondrial protein that is highly homologous to yeast activity of *bcl* complex. *Cancer Res*. 2002;62:1246–50. [PubMed: 11888884]
29. Jakobs BS, van den Heuvel LP, Smeets RJ, de Vries MC, Hien S, Schaible T, Smeitink JA, Wevers RA, Wortmann SB, Rodenburg RJ. A novel mutation in *COQ2* leading to fatal infantile multisystem disease. *J Neurol Sci*. 2013;326:24–8. [PubMed: 23343605]
30. Jeon BS, Farrer MJ, Bortnick SF. Mutant *COQ2* in multiple-system atrophy. *N Engl J Med*. 2014;371:80. [PubMed: 24988567]
31. Khadria AS, Mueller BK, Stefely JA, Tan CH, Pagliarini DJ, Senes A. A Gly-zipper motif mediates homodimerization of the transmembrane domain of the mitochondrial kinase *ADCK3*. *J Am Chem Soc*. 2014;136:14068–77. [PMC free article: PMC4195374] [PubMed: 25216398]
32. Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, Gribouval O, Fourrage C, Tabatabaei M, Schnaidt S, Gucer S, Kaymaz F, Arici M, Dinckan A, Mir S, Bayazit AK, Emre S, Balat A, Rees L, Shroff R, Bergmann C, Mourani C, Antignac C, Ozaltin F, Schaefer F, et al. ADCK4-associated glomerulopathy causes adolescence-onset FSGS. *J Am Soc Nephrol*. 2016;27:63–8. [PMC free article: PMC4696579] [PubMed: 25967120]
33. Lagier-Tourenne C, Tazir M, López LC, Quinzii CM, Assoum M, Drouot N, Busso C, Makri S, Ali-Pacha L, Benhassine T, Anheim M, Lynch DR, Thibault C, Plewniak F, Bianchetti L, Tranchant C, Poch O, DiMauro S, Mandel JL, Barros MH, Hirano M, Koenig M. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. *Am J Hum Genet*. 2008;82:661–72. [PMC free article: PMC2427193] [PubMed: 18319074]
34. Liu YT, Hersheson J, Plagnol V, Fawcett K, Duberley KE, Preza E, Hargreaves IP, Chalasani A, Laurá M, Wood NW, Reilly MM, Houlden H. Autosomal-recessive cerebellar ataxia caused by a novel *ADCK3* mutation that elongates the protein: clinical, genetic and biochemical characterisation. *J Neurol Neurosurg Psychiatry*. 2014;85:493–8. [PMC free article: PMC3995328] [PubMed: 24218524]

35. Lohman DC, Forouhar F, Beebe ET, Stefely MS, Minogue CE, Ulbrich A, Stefely JA, Sukumar S, Luna-Sánchez M, Jochem A, Lew S, Seetharaman J, Xiao R, Wang H, Westphall MS, Wrobel RL, Everett JK, Mitchell JC, López LC, Coon JJ, Tong L, Pagliarini DJ. Mitochondrial COQ9 is a lipid-binding protein that associates with COQ7 to enable coenzyme Q biosynthesis. *Proc Natl Acad Sci U S A*. 2014;111:E4697–705. [PMC free article: [PMC4226113](#)] [PubMed: [25339443](#)]
36. López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, Dimauro S, Hirano M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. *Am J Hum Genet*. 2006;79:1125–9. [PMC free article: [PMC1698707](#)] [PubMed: [17186472](#)]
37. López LC, Quinzii CM, Area E, Naini A, Rahman S, Schuelke M, Salviati L, Dimauro S, Hirano M. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. *PLoS One*. 2010;5:e11897. [PMC free article: [PMC2912846](#)] [PubMed: [20689595](#)]
38. López-Martín JM, Salviati L, **Trevisson** E, Montini G, DiMauro S, Quinzii C, Hirano M, Rodriguez-Hernandez A, Cordero MD, Sánchez-Alcázar JA, Santos-Ocaña C, Navas P. Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. *Hum Mol Genet*. 2007;16:1091–7. [PMC free article: [PMC4345105](#)] [PubMed: [17374725](#)]
39. Marbois B, Gin P, Gulmezian M, Clarke CF. The yeast Coq4 polypeptide organizes a mitochondrial protein complex essential for coenzyme Q biosynthesis. *Biochim Biophys Acta*. 2009;1791:69–75. [PMC free article: [PMC2627766](#)] [PubMed: [19022396](#)]
40. McCarthy HJ, Bierzynska A, Wherlock M, Ognjanovic M, Kerecuk L, Hegde S, Feather S, Gilbert RD, Krischock L, Jones C, Sinha MD, Webb NJ, Christian M, Williams MM, Marks S, Koziell A, Welsh GI, Saleem MA., RADAR the UK SRNS Study Group. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol*. 2013;8:637–48. [PMC free article: [PMC3613958](#)] [PubMed: [23349334](#)]
41. Mignot C, Apartis E, Durr A, Marques Lourenço C, Charles P, Devos D, Moreau C, de Lonlay P, Drouot N, Burglen L, Kempf N, Nourisson E, Chantot-Bastaraud S, Lebre AS, Rio M, Chaix Y, Bieth E, Roze E, Bonnet I, Canaple S, Rastel C, Brice A, Rötig A, Desguerre I, Tranchant C, Koenig M, Anheim M. Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression. *Orphanet J Rare Dis*. 2013;8:173. [PMC free article: [PMC3843540](#)] [PubMed: [24164873](#)]
42. Mitsui J, Matsukawa T, Ishiura H, Fukuda Y, Ichikawa Y, Date H, Ahsan B, Nakahara Y, Momose Y, Takahashi Y, Iwata A, Goto J, Yamamoto Y, Komata M, Shirahige K, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Takashima H, Kuwano R, Watanabe H, Ito M, Sobue G, Soma H, Yabe I, Sasaki H, Aoki M, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, Toda T, Dürr A, Brice A, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Shults CW, Tanner CM, Kukull WA, Lee VM, Masliah E, Low PA, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T, Tsuji S. Mutations in COQ2 in familial and sporadic multiple-system atrophy. *N Engl J Med*. 2013;369:233–44.
43. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, Lombes A, Boddaert N, Desguerre I, de Lonlay P, de Baulny HO, Munnich A, Rötig A. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. *Am J Hum Genet*. 2008;82:623–30. [PMC free article: [PMC2427298](#)] [PubMed: [18319072](#)]
44. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, Bacq D, de Lonlay P, Munnich A, Rötig A. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. *J Clin Invest*. 2007;117:765–72. [PMC free article: [PMC1804361](#)] [PubMed: [17332895](#)]

45. Montero R, Sánchez-Alcázar JA, Briones P, Hernández AR, Cordero MD, **Trevisson E**, Salviati L, Pineda M, García-Cazorla A, Navas P, Artuch R. Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes. *Clin Biochem.* 2008;41:697–700. [PubMed: 18387363]
46. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N Engl J Med.* 2008;358:2849–50. [PubMed: 18579827]
47. Ozeir M, Mühlenhoff U, Webert H, Lill R, Fontecave M, Pierrel F. Coenzyme Q biosynthesis: Coq6 is required for the C5-hydroxylation reaction and substrate analogs rescue Coq6 deficiency. *Chem Biol.* 2011;18:1134–42. [PubMed: 21944752]
48. Quinzii C, Naini A, Salviati L, **Trevisson E**, Navas P, Dimauro S, Hirano M. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. *Am J Hum Genet.* 2006;78:345–9. [PMC free article: PMC1380241] [PubMed: 16400613]
49. Quinzii CM, López LC, Gilkerson RW, Dorado B, Coku J, Naini AB, Lagier-Tourenne C, Schuelke M, Salviati L, Carozzo R, Santorelli F, Rahman S, Tazir M, Koenig M, DiMauro S, Hirano M. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. *FASEB J.* 2010;24:3733–43. [PMC free article: PMC2996902] [PubMed: 20495179]
50. Rahman S, Clarke CF, Hirano M. The 176th ENMC International Workshop: diagnosis and treatment of coenzyme Q10 deficiency. *Neuromuscul Disord.* 2012;22:76–86. [PMC free article: PMC3222743] [PubMed: 21723727]
51. Rötig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, Edery P, Lebideau M, Dallner G, Munnich A, Ernster L, Rustin P. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. *Lancet.* 2000;356:391–5. [PubMed: 10972372]
52. Saiki R, Lunceford AL, Shi Y, Marbois B, King R, Pachuski J, Kawamukai M, Gasser DL, Clarke CF. Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2. *Am J Physiol Renal Physiol.* 2008;295:F1535–44. [PMC free article: PMC2584909] [PubMed: 18784258]
53. Saiki R, Nagata A, Kainou T, Matsuda H, Kawamukai M. Characterization of solanesyl and decaprenyl diphosphate synthases in mice and humans. *FEBS J.* 2005;272:5606–22. [PubMed: 16262699]
54. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, Basso G, Quinzii C, Angelini C, Hirano M, Naini AB, Navas P, DiMauro S, Montini G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. *Neurology.* 2005;65:606–8. [PubMed: 16116126]
55. Salviati L, **Trevisson E**, Rodriguez Hernandez MA, Casarin A, Pertegato V, Doimo M, Cassina M, Agosto C, Desbats MA, Sartori G, Sacconi S, Memo L, Zuffardi O, Artuch R, Quinzii C, Dimauro S, Hirano M, Santos-Ocaña C, Navas P. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. *J Med Genet.* 2012;49:187–91. [PMC free article: PMC3983946] [PubMed: 22368301]
56. Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, Seneca S, Lissens W, Ribes A, Geers C, Smet J, De Meirleir L. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). *Eur J Paediatr Neurol.* 2013;17:625–30. [PubMed: 23816342]
57. Schottlaender LV, Houlden H. Mutant COQ2 in multiple-system atrophy. *N Engl J Med.* 2014;371:81. [PubMed: 24988569]
58. Sharma M, Wenning G, Kruger R. Mutant COQ2 in multiple-system atrophy. *N Engl J Med.* 2014;371:80–81. [PubMed: 24988568]
59. Stefely JA, Reidenbach AG, Ulbrich A, Oruganty K, Floyd BJ, Jochem A, Saunders JM, Johnson IE, Minogue CE, Wrobel RL, Barber GE, Lee D, Li S, Kannan N, Coon JJ, Bingman CA, Pagliarini DJ. Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis. *Mol Cell.* 2015;57:83–94. [PMC free

article: PMC4289473] [PubMed: 25498144]

60. Terracciano A, Renaldo F, Zanni G, D'Amico A, Pastore A, Barresi S, Valente EM, Piemonte F, Tozzi G, Carrozzo R, Valeriani M, Boldrini R, Mercuri E, Santorelli FM, Bertini E. The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children. *Eur J Paediatr Neurol.* 2012;16:248–56. [PMC free article: PMC3341568] [PubMed: 21873089]
61. **Trevisson E**, DiMauro S, Navas P, Salviati L. Coenzyme Q deficiency in muscle. *Curr Opin Neurol.* 2011;24:449–56. [PubMed: 21844807]
62. **Trevisson E**, Clementi M, Salviati L. Is there a link between COQ6 and schwannomatosis? *Genet Med.* 2015;17:312–3. [PubMed: 25835193]
63. Vasta V, Merritt JL 2nd, Saneto RP, Hahn SH. Next-generation sequencing for mitochondrial diseases: a wide diagnostic spectrum. *Pediatr Int.* 2012;54:585–601. [PubMed: 22494076]
64. Wheeler B, Jia Z. Preparation and characterization of human ADCK3, a putative atypical kinase. *Protein Expr Purif.* 2015;108:13–7. [PubMed: 25540914]
65. Yubero D, Montero R, Armstrong J, Espinós C, Palau F, Santos-Ocaña C, Salviati L, Navas P, Artuch R. Molecular diagnosis of coenzyme Q(10) deficiency. *Expert Rev Mol Diagn.* 2015;15:1049–59. [PubMed: 26144946]

## Chapter Notes

---

### Acknowledgments

This work is supported by Telethon Italy Grants GGP13222 and GGP14187, a grant from Fondazione CARIPARO, and University of Padova Grant CPDA123573/12 (to LS) and from Ministry of Health Grant GR-2009-1578914 to (ET).

### Revision History

- 26 January 2017 (bp) Review posted live
- 20 February 2015 (ls) Original submission

Copyright © 1993–2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993–2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).

Bookshelf ID: NBK410087 PMID: 28125198